AU2022291395A1 - Neuroactive steroid for the treatment of alzheimer's disease - Google Patents

Neuroactive steroid for the treatment of alzheimer's disease Download PDF

Info

Publication number
AU2022291395A1
AU2022291395A1 AU2022291395A AU2022291395A AU2022291395A1 AU 2022291395 A1 AU2022291395 A1 AU 2022291395A1 AU 2022291395 A AU2022291395 A AU 2022291395A AU 2022291395 A AU2022291395 A AU 2022291395A AU 2022291395 A1 AU2022291395 A1 AU 2022291395A1
Authority
AU
Australia
Prior art keywords
subject
compound
pharmaceutically acceptable
acceptable salt
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022291395A
Other languages
English (en)
Inventor
James J. DOHERTY
Aaron Michael KOENIG
Michael C. QUIRK
Albert Jean Robichaud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sage Therapeutics Inc
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of AU2022291395A1 publication Critical patent/AU2022291395A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022291395A 2021-06-11 2022-06-10 Neuroactive steroid for the treatment of alzheimer's disease Pending AU2022291395A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163209929P 2021-06-11 2021-06-11
US63/209,929 2021-06-11
US202163289081P 2021-12-13 2021-12-13
US63/289,081 2021-12-13
US202263321598P 2022-03-18 2022-03-18
US63/321,598 2022-03-18
PCT/US2022/033122 WO2022261510A1 (en) 2021-06-11 2022-06-10 Neuroactive steroid for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
AU2022291395A1 true AU2022291395A1 (en) 2024-01-04

Family

ID=82361350

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022291395A Pending AU2022291395A1 (en) 2021-06-11 2022-06-10 Neuroactive steroid for the treatment of alzheimer's disease

Country Status (9)

Country Link
US (1) US20250319105A1 (https=)
EP (1) EP4351588A1 (https=)
JP (1) JP2024520805A (https=)
KR (1) KR20240035444A (https=)
AU (1) AU2022291395A1 (https=)
CA (1) CA3223179A1 (https=)
IL (1) IL309208A (https=)
MX (1) MX2023014719A (https=)
WO (1) WO2022261510A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3828194B1 (en) 2015-07-06 2025-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP4704905A1 (en) * 2023-05-02 2026-03-11 Sage Therapeutics, LLC Lymphatic system-targeting compounds
TW202508603A (zh) * 2023-05-02 2025-03-01 美商賽吉醫療公司 神經活性類固醇調配物及其使用方法
WO2025021195A1 (zh) * 2023-07-27 2025-01-30 珂阑(上海)医药科技有限公司 甾类化合物、其制备方法和应用
WO2025020190A1 (zh) * 2023-07-27 2025-01-30 珂阑(上海)医药科技有限公司 甾类化合物、其制备方法和应用
WO2025020191A1 (zh) * 2023-07-27 2025-01-30 珂阑(上海)医药科技有限公司 甾类化合物、其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
KR20080073293A (ko) 2005-10-14 2008-08-08 메디뮨 엘엘씨 항체 라이브러리의 세포 디스플레이
WO2008081008A1 (en) 2007-01-05 2008-07-10 University Of Zurich Method of providing disease-specific binding molecules and targets
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
HUE030100T2 (en) 2010-02-19 2017-04-28 Xencor Inc New CTLA4-IG immunoadhesins
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
CA2848212C (en) 2011-09-08 2022-03-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
AP2014007606A0 (en) 2011-10-07 2014-05-31 Takeda Pharmaceutical 1-Arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
JP6249952B2 (ja) 2012-10-16 2017-12-20 武田薬品工業株式会社 複素環化合物
HUE039922T2 (hu) 2012-12-11 2019-02-28 Takeda Pharmaceuticals Co Heterociklusos vegyületek
PT2968369T (pt) 2013-03-13 2018-12-05 Sage Therapeutics Inc Esteroides neuroativos e métodos para o seu uso
JP6272833B2 (ja) 2013-04-04 2018-01-31 武田薬品工業株式会社 複素環化合物
EP3102230B1 (en) * 2014-02-08 2021-04-28 F. Hoffmann-La Roche AG Methods of treating alzheimer's disease
US10259840B2 (en) 2014-06-18 2019-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
CA2991311C (en) 2015-07-06 2025-05-06 Sage Therapeutics, Inc. OXYSTEROLS AND THEIR METHODS OF USE
EP3828194B1 (en) 2015-07-06 2025-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
HUE071964T2 (hu) 2015-07-06 2025-10-28 Sage Therapeutics Inc Oxiszterolok és alkalmazási eljárásaik
US10562881B2 (en) 2015-10-16 2020-02-18 Takeda Pharmaceutical Company Limited Method for producing heterocyclic compound
SMT202200300T1 (it) 2016-04-01 2022-09-14 Sage Therapeutics Inc Ossisteroli e relativi metodi d'uso
CA3021634A1 (en) 2016-04-15 2017-10-19 Zymeworks Inc. Multi-specific antigen-binding constructs targeting immunotherapeutics
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
ES2884071T3 (es) 2016-07-07 2021-12-10 Sage Therapeutics Inc 24-hidroxiesteroles sustituidos en 11 para el tratamiento de afecciones relacionadas con NMDA
CA3038984A1 (en) 2016-09-30 2018-04-05 Schlumberger Canada Limited Fiber measurements for fluid treatment processes in a well
RU2019115113A (ru) 2016-10-18 2020-11-24 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
TW202523658A (zh) 2019-05-24 2025-06-16 美商賽吉醫療公司 化合物、組合物及使用方法
WO2022115620A1 (en) 2020-11-25 2022-06-02 Sage Therapeutics, Inc. 4-fluoro-(4-(4-benzyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone derivatives and similar compounds as cyp46a1 inhibitors for the treatment of neurodegenerative disorders

Also Published As

Publication number Publication date
WO2022261510A1 (en) 2022-12-15
KR20240035444A (ko) 2024-03-15
MX2023014719A (es) 2024-02-15
JP2024520805A (ja) 2024-05-24
IL309208A (en) 2024-02-01
US20250319105A1 (en) 2025-10-16
CA3223179A1 (en) 2022-12-15
EP4351588A1 (en) 2024-04-17

Similar Documents

Publication Publication Date Title
EP4351588A1 (en) Neuroactive steroid for the treatment of alzheimer's disease
CA2953809C (en) Humanized anti-tau antibodies
JP6685912B2 (ja) アルツハイマー病治療方法
CN114539414B (zh) 抗凝血因子xi抗体
AU2020210233B2 (en) Anti-coagulation factor XI antibodies
TW201716436A (zh) 特異性針對過度磷酸化τ蛋白之抗體及其使用方法
US20240383972A1 (en) Methods of treating tau pathologies
HUE029824T2 (en) Novel antagonist antibodies and their fab fragments against gpvi and uses thereof
CA2626783A1 (en) Anti-addl monoclonal antibody and use thereof
WO2012009442A2 (en) Anti-addl monoclonal antibody and uses thereof
US20250115671A1 (en) Anti-ccr8 antibodies and methods of use
CN117769425A (zh) 用于治疗阿尔茨海默氏病的神经活性类固醇
WO2026033259A1 (en) Antibodies for treating neurological and neurovascular disorders
HK40035893A (en) Methods of treating alzheimer's disease
NZ765680A (en) Humanized anti-tau antibodies